--- title: "Quantum BioPharma stock surges on MS imaging study progress" type: "News" locale: "en" url: "https://longbridge.com/en/news/286775364.md" description: "Quantum BioPharma Ltd. (NASDAQ:QNTM) shares surged 10% in premarket trading after announcing that patient enrollment in its MS imaging study with Massachusetts General Hospital has reached the halfway point, showing promising preliminary results. The study aims to validate a PET imaging technique for assessing demyelinated neurons in multiple sclerosis patients. The imaging approach may enhance the evaluation of treatments, including Quantum's investigational candidate, Lucid-MS, which targets myelin degradation." datetime: "2026-05-18T12:55:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286775364.md) - [en](https://longbridge.com/en/news/286775364.md) - [zh-HK](https://longbridge.com/zh-HK/news/286775364.md) --- # Quantum BioPharma stock surges on MS imaging study progress Investing.com - Quantum BioPharma Ltd. (NASDAQ:QNTM) shares rose 10% in premarket trading Monday following the company’s announcement that patient enrollment in its collaborative study with Massachusetts General Hospital reached the halfway mark with encouraging preliminary imaging results.The study is designed to validate a positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis. The research utilizes the PET tracer \[¹⁸F\] 3F4AP, developed by Pedro Brugarolas, an investigator in the Department of Radiology at MGH and Assistant Professor at Harvard Medical School.The first cohort of participants has been successfully imaged using both advanced PET/MR and total-body PET platforms. Preliminary analyses indicate robust signal in acute MS lesions and potential sensitivity to gray matter lesions, according to the company."We are excited to reach this important midpoint in our study with MGH and encouraged by the strength of the preliminary imaging data," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum BioPharma.The imaging approach could enable more precise measurement of how therapies impact myelin preservation and regeneration, potentially enhancing the evaluation of treatments including Quantum’s investigational candidate, Lucid-MS (Lucid-21-302).Lucid-MS is designed to provide neuroprotection through the inhibition of demyelination by targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. The company submitted an IND for Phase 2 approval to the FDA in March 2026.In prior Phase 1 clinical trials, Lucid-MS demonstrated a favorable safety profile and was well-tolerated in healthy participants.This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. ### Related Stocks - [QNTM.US](https://longbridge.com/en/quote/QNTM.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) ## Related News & Research - [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md) - [Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push](https://longbridge.com/en/news/286623100.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md) - [](https://longbridge.com/en/news/286787081.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)